Skip to main content

Schizophrenia & Psychotic Disorders

Pimavanserin, currently approved by the US Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis, reduced the risk of psychosis relapse 2.8-fold in patients with dementia.
A polygenic risk score incorporating data from recent schizophrenia and bipolar genome-wide association studies predicted which high-risk patients with European ancestry went on to develop psychosis.
In a large sample of people at high risk for psychosis, baseline abnormalities in recognizing negative emotion were associated with a low level of overall functioning at a 12-month follow-up.
Alkermes has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of the investigational drug ALKS 3831, a combination of the antipsychotic olanzapine and samidorphan, a novel molecular entity.
Higher scores in grandiosity at baseline were significantly associated with relapse in patients with schizophrenia who received oral antipsychotics, according to a study published online in Schizophrenia Research.

Psych Congress co-chair Rakesh Jain, MD, MPH, explains the importance of the Abnormal Involuntary Movement Scale (AIMS) exam in the diagnosis and monitoring of patients with tardive…

What does in utero malnutrition have to do with schizophrenia? And why is weight gain, a problematic adverse event, also linked with clinical effectiveness of antipsychotic medications? 
Why do so many antipsychotic medications induce symptoms, signs, and physiologic changes that are already present to a lesser degree in the disease states that they are intended to treat?
Back to Top